Table 2.
Adrenaline output (ng min−1) | ||||
---|---|---|---|---|
1st trial | 2nd trial | 3rd trial | 4th trial | |
Group 3 (n= 16) | ||||
DMPP 5 μm | 13.4 ± 3.1 | 13.7 ± 3.6 | 15.0 ± 4.8 | 18.2 ± 3.9 |
DMPP 10 μm | 55.1 ± 7.7 | 62.9 ± 10.4 | 59.4 ± 9.7 | 58.6 ± 8.7 |
DMPP 20 μm | 143.3 ± 17.4 | 150.7 ± 17.1 | 137.4 ± 14.2 | 140.9 ± 12.3 |
DMPP 40 μm | 192.9 ± 20.7 | 198.7 ± 22.1 | 188.3 ± 16.9 | 192.8 ± 19.9 |
Group 4 (n= 15) | ||||
MCh 10 μm | 22.6 ± 5.0 | 15.6 ± 3.9 | 11.8 ± 3.4 | 9.0 ± 3.3 |
MCh 30 μm | 46.3 ± 9.7 | 53.2 ± 9.6 | 46.3 ± 7.6 | 36.6 ± 7.1 |
MCh 100 μm | 89.7 ± 15.5 | 105.5 ± 16.9 | 98.3 ± 15.5 | 91.3 ± 13.8 |
MCh 300 μm | 130.9 ± 21.1 | 150.2 ± 21.9 | 133.2 ± 22.1 | 150.6 ± 19.5 |
Noradrenaline output (ng min−1) | ||||
---|---|---|---|---|
1st trial | 2nd trial | 3rd trial | 4th trial | |
Group 3 (n= 16) | ||||
DMPP 5 μm | 1.6 ± 0.3 | 1.8 ± 0.4 | 1.5 ± 0.4 | 2.0 ± 0.4 |
DMPP 10 μm | 8.2 ± 1.2 | 10.0 ± 1.7 | 9.0 ± 1.3 | 8.7 ± 1.6 |
DMPP 20 μm | 27.8 ± 3.6 | 30.0 ± 3.6 | 26.8 ± 3.4 | 25.4 ± 3.0 |
DMPP 40 μm | 55.5 ± 6.7 | 56.6 ± 7.9 | 54.6 ± 5.8 | 51.3 ± 5.2 |
Group 4 (n= 15) | ||||
MCh 10 μm | 0.7 ± 0.2 | 0.2 ± 0.2 | 0.1 ± 0.1 | 0.2 ± 0.2 |
MCh 30 μm | 1.7 ± 0.5 | 2.1 ± 0.4 | 1.6 ± 0.4 | 1.5 ± 0.4 |
MCh 100 μm | 5.2 ± 1.1 | 6.5 ± 1.2 | 6.4 ± 1.1 | 5.5 ± 1.1 |
MCh 300 μm | 12.5 ± 2.0 | 14.8 ± 2.3 | 13.1 ± 2.3 | 15.7 ± 2.0 |
Values are means ± s.e.m.; n= number of rats per group. There were no significant differences (P > 0.05) between the values during the 1st trial and those during the 2nd, 3rd or 4th trials.